James N. Topper Acquires 1,135 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper purchased 1,135 shares of the stock in a transaction on Wednesday, March 26th. The stock was acquired at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the acquisition, the director now owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. This represents a 0.04 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this link.

NewAmsterdam Pharma Stock Down 2.9 %

Shares of NASDAQ:NAMS opened at $21.76 on Friday. The stock has a market cap of $2.39 billion, a PE ratio of -8.37 and a beta of -0.04. The company’s fifty day moving average is $21.66 and its 200 day moving average is $21.23. NewAmsterdam Pharma has a 52 week low of $15.19 and a 52 week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $3.30 million. Sell-side analysts anticipate that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors have recently made changes to their positions in NAMS. Deerfield Management Company L.P. Series C increased its stake in shares of NewAmsterdam Pharma by 378.4% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company’s stock worth $110,879,000 after buying an additional 3,412,590 shares during the period. Frazier Life Sciences Management L.P. increased its position in shares of NewAmsterdam Pharma by 23.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock valued at $409,052,000 after acquiring an additional 3,061,224 shares during the period. Jennison Associates LLC raised its stake in shares of NewAmsterdam Pharma by 291.9% during the fourth quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock valued at $102,763,000 after acquiring an additional 2,978,263 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of NewAmsterdam Pharma by 2,410.4% during the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company’s stock worth $59,499,000 after purchasing an additional 2,222,900 shares during the period. Finally, Capital International Investors bought a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth about $53,007,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NAMS. Scotiabank raised their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Royal Bank of Canada restated an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. HC Wainwright reiterated a “buy” rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research note on Monday, March 3rd. Finally, Needham & Company LLC dropped their price target on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma presently has an average rating of “Buy” and an average target price of $43.33.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.